| abstract |
(57) [Summary] (Modified) [Structure] 1 to 20 containing the novel peptide sequence of the general formula (I) or a pharmacologically acceptable salt thereof as an essential constituent unit. A cancer metastasis inhibitor containing a peptide derivative containing a unit. (I) [Z] -Arg-X-Asp- [Y] Arg is L- or D-arginine, Asp is L-aspartic acid, X is L- or D-leucine, D-isoleucine, L- or D-. Represents norleucine, L- or D-phenylalanine, D-phenylglycine or D-alanine. The residue in [] may or may not be present, and when present, Z and Y are glycine, L-serine, L-threonine, D- and L-aspartic acid, L-alanine, D- and L, respectively. -Represents an amino acid selected from glutamic acid and L-proline, or a peptide combining these. [Effect] This peptide derivative has a higher cancer metastasis inhibitory action than the core sequence of the cell adhesive protein, and has almost no toxicity problem. It has a simple structure and is easy to synthesize, and is highly valuable as a medicine. |